These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16999848)

  • 1. Are placebo-controlled trials ethical in areas where current guidelines recommend therapy? Yes.
    Cohen AT; Maillardet LM
    J Thromb Haemost; 2006 Oct; 4(10):2130-2. PubMed ID: 16999848
    [No Abstract]   [Full Text] [Related]  

  • 2. Are placebo-controlled trials ethical in areas where current guidelines recommend therapy? No.
    Iorio A; Agnelli G
    J Thromb Haemost; 2006 Oct; 4(10):2133-6. PubMed ID: 16848864
    [No Abstract]   [Full Text] [Related]  

  • 3. The safety of fondaparinux for the prevention and treatment of venous thromboembolism.
    Turpie AG
    Expert Opin Drug Saf; 2005 Jul; 4(4):707-21. PubMed ID: 16011449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors.
    Nutescu EA; Helgason CM
    Pharmacotherapy; 2004 Jul; 24(7 Pt 2):82S-87S. PubMed ID: 15317403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and emerging options in the management of venous thromboembolism.
    Jaffer AK; Brotman DJ; Michota F
    Cleve Clin J Med; 2005 Apr; 72 Suppl 1():S14-23. PubMed ID: 15853175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.
    Davidson BL; Büller HR; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob GE; Segers AE; Lensing AW;
    J Thromb Haemost; 2007 Jun; 5(6):1191-4. PubMed ID: 17403087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.
    Bauer KA; Eriksson BI; Lassen MR; Turpie AG
    Curr Opin Pulm Med; 2002 Sep; 8(5):398-404. PubMed ID: 12172443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism.
    Robinson DM; Wellington K
    Am J Cardiovasc Drugs; 2005; 5(5):335-46. PubMed ID: 16156690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance?
    Lowe GD; Sandercock PA; Rosendaal FR
    Lancet; 2003 Aug; 362(9383):504-5. PubMed ID: 12932379
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of venous thromboembolism: duration and new options.
    Huisman MV
    Hematol J; 2004; 5 Suppl 3():S24-8. PubMed ID: 15190273
    [No Abstract]   [Full Text] [Related]  

  • 11. The safety of fondaparinux sodium for the treatment of venous thromboembolism.
    Mastroiacovo D; Sala G; Dentali F
    Expert Opin Drug Saf; 2016 Sep; 15(9):1259-65. PubMed ID: 27537418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New anticoagulants in the treatment of venous thrombo-embolic disease].
    Bura-Riviere A; Fiessinger JN
    Rev Med Interne; 2003 Nov; 24(11):738-44. PubMed ID: 14604751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fondaparinux: an update on new study results.
    Bauersachs RM
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():27-32. PubMed ID: 15701145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
    Turpie AG; Bauer KA; Eriksson BI; Lassen MR
    Arch Intern Med; 2002 Sep; 162(16):1833-40. PubMed ID: 12196081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New anticoagulants for the prevention and treatment of venous thromboembolism.
    McRae SJ; Ginsberg JS
    Vasc Health Risk Manag; 2005; 1(1):41-53. PubMed ID: 17319097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fondaparinux: a potential new therapy for HIT.
    Kuo KH; Kovacs MJ
    Hematology; 2005 Aug; 10(4):271-5. PubMed ID: 16085538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential role of fondaparinux as venous thromboembolism prophylaxis after total hip or knee replacement or hip fracture surgery.
    Heit JA
    Arch Intern Med; 2002 Sep; 162(16):1806-8. PubMed ID: 12196077
    [No Abstract]   [Full Text] [Related]  

  • 18. Fondaparinux (Arixtra): a new anticoagulant.
    Giangrande PL
    Int J Clin Pract; 2002 Oct; 56(8):615-7. PubMed ID: 12425373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.
    Cohen AT; Davidson BL; Gallus AS; Lassen MR; Prins MH; Tomkowski W; Turpie AG; Egberts JF; Lensing AW;
    BMJ; 2006 Feb; 332(7537):325-9. PubMed ID: 16439370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.